AURKA and neoplasm: No statistically significant difference in PFS was noted among patients with high vs low AURKA-CN tumours in the group overall (10.4 months vs 7.7 months; HR=0.54, 95% CI: 0.24–1.19, P=0.13; Figure 3C).